The FTC filed a contempt motion against Amare Global Holdings, Shawn Talbott, Patrick Hintze, and Hiep Tran for allegedly violating a 2005 FTC order that prohibited Talbott from making unsubstantiated health claims. The motion alleges that the defendants marketed dietary supplements for children and adults with false claims about treating depression, anxiety, and ADHD, and misrepresented scientific evidence. The FTC seeks compensatory damages for consumers.
The FTC is seeking compensatory damages for consumers in the full amount paid for the at-issue products, and an order holding the defendants in contempt for violating the prior FTC order.
In-house legal teams should review vendor agreements with marketing and supplement companies to ensure clauses require competent and reliable scientific evidence for all health claims. They should also check for compliance with prior FTC orders and include provisions for indemnification if claims are found unsubstantiated. Additionally, contracts with brand partners or affiliates should mandate adherence to FTC guidelines and prohibit making false or misleading representations.
Entity
Amare Global Holdings
Industry
OtherOfficial Press Release
https://www.ftc.gov/news-events/news/press-releases/2026/06/ftc-files-contempt-motion-against-amare-global-three-individuals-over-unsubstantiated-health-claims
2523140amareglobalcontemptmotion
https://www.ftc.gov/system/files/ftc_gov/pdf/2523140amareglobalcontemptmotion.pdf
Federal Trade Commission Enforcement Page
https://www.ftc.gov/enforcement
"Amare Global Holdings"
"unsubstantiated health and efficacy claims concerning Amare’s products, including that they boost neurotransmitters like serotonin and dopamine, lower cortisol and can cure, treat or mitigate the symptoms of conditions like depression, anxiety and ADHD"
"compensatory damages for consumers in the full amount consumers paid for the at-issue products"
"FTC order that banned Talbott and those who work with him from making false, deceptive or unsubstantiated health claims"
$750K
The FTC finalized an order against Vanilla Chip LLC (doing business as TruHeight) and its principals for deceptively advertising height-enhancing supplements for children and teens without scientific evidence. The company also used fake reviews and incentivized 5-star ratings. The order requires a $750,000 payment and prohibits false health claims and deceptive review practices.
$2.3M
The FTC alleged that RentGrow, a tenant screening company, violated the Fair Credit Reporting Act (FCRA) by failing to use reasonable procedures to ensure the accuracy of its reports, including by reporting duplicate records and failing to disclose data sources. RentGrow agreed to pay a $2.25 million penalty and is prohibited from further FCRA violations and from misrepresenting dispute outcomes.
The FTC and New York Attorney General took action against Handy Technologies for deceptive earnings claims and failure to disclose fees and fines that led to millions of dollars being withheld from workers' wages. The FTC is sending over $2.7 million in refunds to 62,893 affected consumers.
$35.0M
The FTC alleged that Hopper, a travel booking app, charged consumers hidden and pre-selected fees (Tip and VIP Support) without their consent, misrepresented the benefits of VIP Support and Price Freeze services, and failed to clearly disclose total prices. Hopper agreed to pay $35 million for consumer redress and is prohibited from misrepresenting fees under a proposed order.
$1.5M
The FTC finalized a settlement with Publishing.com LLC and its principals for misleading consumers about potential earnings from self-publishing products. The company will pay $1.5 million and is prohibited from making unsubstantiated earnings claims, failing to disclose refund terms, and misrepresenting endorsements and reviews.
The FTC is seeking public comment on a proposed policy statement addressing concerns that AI companies may be manipulating AI system outputs contrary to consumer expectations for objectivity and accuracy. The statement explains that such conduct could be considered deceptive under Section 5 of the FTC Act. The public comment period runs until July 31, 2026.